Please provide your email address to receive an email when new articles are posted on . Dapirolizumab pegol met its primary endpoint, achieving clinical improvement, when combined with ...

Biogen Inc. BIIB, along with its Belgian partner UCB, announced positive topline data from the phase III PHOENYCS GO study, which evaluated the investigational drug candidate, dapirolizumab pegol, for ...

Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and ...

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary ...

In 2024, UCB and Biogen will initiate a second Phase 3 trial of dapirolizumab pegol, PHOENYCS FLY (NCT06617325). The safety and efficacy of dapirolizumab pegol in systemic lupus erythematosus have not ...

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus ...

UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab ...

UCB and Biogen have announced positive Phase III clinical trial results for PHOENYCS GO study, evaluating dapirolizumab pegol, a new treatment for moderate-to-severe systemic lupus erythematosus (SLE) ...

Please provide your email address to receive an email when new articles are posted on . Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and ...